C-peptide vs Somatostatin
Head-to-head comparison of C-peptide (Connecting peptide (C-peptide)) and Somatostatin (Somatostatin-14) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | C-peptide | Somatostatin |
|---|---|---|
| Category | Pain Management | Pain Management |
| Full Name | Connecting peptide (C-peptide) | Somatostatin-14 |
| Molecular Weight | 3020.3 Da | 1637.85 |
| Half-Life | ~20-30 min | 1-3 min |
| Amino Acids | 31 | 14 |
| Typical Dose | no approved analgesic dose|research-only | N/A|N/A |
| Route | IV|subQ | IV/SC |
| Purity | ≥98% | ≥98% |
| Studies Count | 46 | 84 |
| Research Status | Pre-clinical | Approved |
C-peptide Benefits
- ✓diabetic neuropathy research
- ✓nerve function support
- ✓possible analgesic effect
Somatostatin Benefits
- ✓nociceptive inhibition
- ✓anti-inflammatory signaling
- ✓visceral pain modulation
C-peptide Dosing
0.5-1.0 mg/day in research|route varies by protocol
Somatostatin Dosing
N/A|N/A
C-peptide Side Effects
- ⚠injection-site reactions
- ⚠unknown long-term safety
Somatostatin Side Effects
- ⚠hyperglycemia
- ⚠bradycardia
- ⚠GI upset
Research Overview
C-peptide
C-peptide is not an approved analgesic, but multiple studies have examined its effects on peripheral nerve blood flow and neuropathy outcomes. The strongest relevance is in diabetic neuropathic pain rather than migraine.
Somatostatin
Somatostatin reduces release of multiple excitatory mediators and can suppress pain signaling in preclinical and limited translational work. Its analgesic use is not standard, but the peptide is real and mechanistically relevant to pain control.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.